Outlook Therapeutics Inc

For the period ended Sep 30, 2024. Filed Dec 27, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Dec 27, 2024

OTLK$0.46+5.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

ITEM 16. Form 10-K Summary

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: December 27, 2024	By:	/s/ Lawrence A. Kenyon
	Name:	Lawrence A. Kenyon
	Title:	Chief Financial Officer and Interim Chief Executive Officer

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

/s/ Ralph H. Thurman	Executive Chairman	December 27, 2024
Ralph H. Thurman
	Chief Financial Officer, Interim Chief Executive Officer,
/s/ Lawrence A. Kenyon	Treasurer, Secretary and Director	December 27, 2024
Lawrence A. Kenyon	(Principal Executive, Financial and Accounting Officer)

/s/ Yezan Haddadin	Director	December 27 2024
Yezan Haddadin

/s/ Kurt J. Hilzinger	Director	December 27, 2024
Kurt J. Hilzinger

/s/ Julia A. Haller	Director	December 27, 2024
Julia A. Haller

/s/ Faisal G. Sukhtian	Director	December 27, 2024
Faisal G. Sukhtian

/s/ Julian Gangolli	Director	December 27, 2024
Julian Gangolli

/s/ Gerd Auffarth	Director	December 27, 2024
Gerd Auffarth

/s/ Andong Huang	Director	December 27, 2024
Andong Huang

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.